Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

• Published in: Cancer immunology research Vol. 3; no. 11; p. 1201
• Main Authors: Glitza, Isabella C, Haymaker, Cara, Bernatchez, Chantale, Vence, Luis, Rohlfs, Michelle, Richard, Jessie, Lacey, Carol, Mansaray, Rahmatu, Fulbright, Orenthial J, Ramachandran, Renjith, Toth, Christopher, Wardell, Seth, Patel, Sapna P, Woodman, Scott E, Hwu, Wen-Jen, Radvanyi, Laszlo G, Davies, Michael A, Papadopoulos, Nicholas E, Hwu, Patrick
• Format: Journal Article
• Language: English
• Published: United States 01.11.2015
• Subjects: Cytokines - cerebrospinal fluid; Disease Progression; Fatal Outcome; Humans; Injections, Spinal; Lymphocytes, Tumor-Infiltrating - transplantation; Male; Melanoma - secondary; Melanoma - therapy; Meningeal Carcinomatosis - therapy; Middle Aged
• ISSN: 2326-6074
• DOI: 10.1158/2326-6066.CIR-15-0071

Patients with leptomeningeal disease (LMD) from melanoma have very poor outcomes and few treatment options. We present a case of intrathecal (i.t.) administration of autologous tumor-infiltrating lymphocytes (TIL) in a patient with LMD from metastatic melanoma. The patient developed LMD after previous treatments with surgery, high-dose bolus interleukin-2 (HD IL2), and systemic TIL infusion and experienced radiographic progression after intrathecal IL2 (i.t. IL2) therapy. The patient received weekly treatment with increasing numbers of i.t. TIL followed by twice-weekly i.t. IL2. The patient received three i.t. TIL infusions and did not experience any toxicities beyond those expected with i.t. IL2 therapy. Analysis of cerebrospinal fluid demonstrated increased inflammatory cytokines following the i.t. Subsequent imaging demonstrated disease stabilization, and neurological deficits also remained stable. The patient expired 5 months after the initiation of i.t. TIL therapy with disease progression in the brain, liver, lung, and peritoneal and retroperitoneal lymph nodes, but without LMD progression. These results demonstrate the safety of i.t. administration of TIL in melanoma patients with LMD and support the feasibility of conducting a prospective clinical trial to determine this therapy's clinical benefit among these patients.